---
figid: PMC6656467__onco12794-fig-0001
figlink: pmc/articles/PMC6656467/figure/onco12794-fig-0001/
number: Figure 1
caption: 'BRAF mutations in the context of mitogen‐activated protein kinase (MAPK)
  molecular alterations. (A): BRAF is an integral component of the intracellular MAPK
  pathway. (B): BRAF V600E mutations encode for a constitutively active BRAF protein,
  leading to overactive MAPK pathway signaling, aberrant proliferation, and cell growth,
  which can drive cancer initiation and progression. (C): In cells that do not harbor
  a BRAF mutation, BRAF inhibitors can lead to paradoxical hyperactivation of BRAF,
  leading to enhanced MAPK signaling and increased cellular proliferation. (D): However,
  mutant BRAF‐specific inhibitors, such as dabrafenib, provide antitumor activity
  in BRAF V600‐mutant tumors by mitigating hyperactive signaling.'
pmcid: PMC6656467
papertitle: Adverse Event Management in Patients with BRAF V600E‐Mutant Non‐Small
  Cell Lung Cancer Treated with Dabrafenib plus Trametinib.
reftext: Anna Chalmers, et al. Oncologist. 2019 Jul;24(7):963-972.
pmc_ranked_result_index: '9666'
pathway_score: 0.8861299
filename: onco12794-fig-0001.jpg
figtitle: BRAF mutations in the context of mitogen‐activated protein kinase (MAPK)
  molecular alterations
year: '2019'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6656467__onco12794-fig-0001.html
  '@type': Dataset
  description: 'BRAF mutations in the context of mitogen‐activated protein kinase
    (MAPK) molecular alterations. (A): BRAF is an integral component of the intracellular
    MAPK pathway. (B): BRAF V600E mutations encode for a constitutively active BRAF
    protein, leading to overactive MAPK pathway signaling, aberrant proliferation,
    and cell growth, which can drive cancer initiation and progression. (C): In cells
    that do not harbor a BRAF mutation, BRAF inhibitors can lead to paradoxical hyperactivation
    of BRAF, leading to enhanced MAPK signaling and increased cellular proliferation.
    (D): However, mutant BRAF‐specific inhibitors, such as dabrafenib, provide antitumor
    activity in BRAF V600‐mutant tumors by mitigating hyperactive signaling.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BRAF
  - HRAS
  - KRAS
  - NRAS
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
  - Dabrafenib
genes:
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
chemicals:
- word: Dabrafenib
  source: MESH
  identifier: C561627
diseases: []
---
